Bremelanotide Production Cost Reports

The report provides a detailed analysis essential for establishing a bremelanotide production plant. It encompasses all critical aspects necessary for bremelanotide production, including the cost of bremelanotide production, bremelanotide plant cost, bremelanotide production costs, and the overall bremelanotide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a bremelanotide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Bremelanotide is a synthetic peptide drug mainly used in the treatment of certain sexual health conditions. It is primarily prescribed for the management of hypoactive sexual desire disorder (HSDD) in premenopausal women, where it helps improve sexual desire and reduce related distress. It works by acting on specific receptors in the brain that are linked to sexual response, helping improve interest and arousal. It is administered through subcutaneous injection and is generally used on an as-needed basis before anticipated sexual activity. In addition, it has also been studied for its potential role in treating sexual dysfunction in men and in certain cases of female sexual arousal disorder. Moreover, it is also used in the medical research sector to explore its effects on mood and appetite regulation due to its action on melanocortin receptors.

The primary factor that drives the market for bremelanotide is its demand in addressing low sexual desire associated with medical causes rather than relationship or psychological factors. Its utilisation as a medication in the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women significantly promotes its demand in the pharmaceutical and speciality therapeutics market. Its involvement in research studies associated with its potential role in treating sexual dysfunction in both men and women also contributes to its demand in the medical research and biotechnology industries.

The increasing awareness of women’s sexual health, growing acceptance of medical treatment for sexual dysfunction, and rising diagnosis rates are contributing to its expanding demand. Moreover, ongoing research into its potential use in other sexual health and related neurological conditions further strengthens its demand in the healthcare industry. Advancements in peptide synthesis technologies, reliable contract production partnerships, compliance with safety regulations, and efficient global distribution systems largely impact global industrial bremelanotide procurement. Factors such as the cost and availability of peptide-based raw materials, strict regulatory approvals, quality control standards, and storage requirements shape procurement decisions for bremelanotide.

Raw Material for Bremelanotide Production

According to the bremelanotide production plant project report, the major raw materials for bremelanotide production include protected amino acids, solid-phase resin, peptide coupling reagents, and suitable solvents used in solid-phase peptide synthesis.

Production Process of Bremelanotide

The extensive bremelanotide production cost report consists of the following industrial production process:

1. Production via Solid-phase Peptide Synthesis: The production process of bremelanotide begins with loading the first Fmoc-protected amino acid onto a solid-phase resin support, which serves as the starting point for building the peptide chain. The remaining protected amino acids are then added in the correct sequence using solid-phase peptide synthesis to form the linear protected peptide intermediate. After assembling the chain, the IVDde protecting group on lysine is selectively removed to expose its amino group. Then, it is coupled with the carboxyl group of an Asp-containing fragment to extend the structure. The completed linear peptide is cleaved from the resin, and the crude product is collected, dried, and subjected to cyclisation to form the required cyclic structure. This cyclized peptide is further treated to remove remaining protecting groups, purified by preparative high-performance liquid chromatography, and finally lyophilised to obtain purified bremelanotide as the desired product.

Bremelanotide is a synthetic cyclic heptapeptide and a melanocortin receptor agonist, derived from alpha-melanocyte-stimulating hormone (α-MSH). In its pure form, it appears as a white lyophilised (freeze-dried) powder, while in its marketed formulation, it is supplied as a sterile, clear solution for subcutaneous injection. The molecular formula of the compound is C50H68N14O10, and its molar mass is 1025.16 g/mol. The acetate form of the compound is freely soluble in water, methanol, and DMSO, and is also soluble in ethanol. The lyophilised form should be stored desiccated below -18 degrees Celsius, while the reconstituted solution should be refrigerated at 2 degrees Celsius to 8 degrees Celsius. The compound decomposes upon heating and does not exhibit a defined atmospheric boiling point. It is administered via subcutaneous injection at least 45 minutes before anticipated sexual activity. It is marketed under the brand name Vyleesi. Common side effects include nausea, vomiting, flushing, headache, and injection site reactions. The compound should not be used by women with uncontrolled high blood pressure or known cardiovascular disease. It is recommended that no more than one dose be administered within a 24-hour period or more than eight doses per month.